


CBR-2092

Chemical Properties

CAS No. : 922717-97-3
 Formula: C₆₅H₈₁FN₆O₁₅
 Molecular Weight: 1205.388
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
 Actual storage temperature shall be subject to the COA.



Biological Description

Description	CBR-2092 is a DNA-directed RNA polymerase and DNA topoisomerase inhibitor. CBR-2092 exhibited rifampin-like potency as an inhibitor of RNA polymerase, was an equipotent (balanced) inhibitor of DNA gyrase and DNA topoisomerase IV, and retained activity against a prevalent quinolone-resistant variant. Studies of mutant strains that exhibited reduced susceptibility to CBR-2092 further substantiated RNA polymerase as the primary cellular target of CBR-2092, with DNA gyrase and DNA topoisomerase IV being secondary and tertiary targets, respectively, in strains exhibiting preexisting rifampin resistance.
Targets(IC50)	Others,Antibacterial,Antibiotic,DNA/RNA Synthesis

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	0.8296 mL	4.148 mL	8.2961 mL
5 mM	0.1659 mL	0.8296 mL	1.6592 mL
10 mM	0.083 mL	0.4148 mL	0.8296 mL
50 mM	0.0166 mL	0.083 mL	0.1659 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Karpiuk I, Tyski S. Looking for the new preparations for antibacterial therapy III. New antimicrobial agents from the quinolones group in clinical trials. *Przegl Epidemiol.* 2013;67(3):455-60, 557-61. English, Polish. PubMed PMID: 24340560.

Prathipati P, Ma NL, Manjunatha UH, Bender A. Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. *J Proteome Res.* 2009 Jun;8(6):2788-98. doi: 10.1021/pr8010843. PubMed PMID: 19301903.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: studies of the mode of action in *Staphylococcus aureus*. *Antimicrob Agents Chemother.* 2008 Jul;52(7):2313-23. doi: 10.1128/AAC.01649-07. PubMed PMID: 18443108; PubMed Central PMCID: PMC2443886.

Robertson GT, Bonventre EJ, Doyle TB, Du Q, Duncan L, Morris TW, Roche ED, Yan D, Lynch AS. In vitro evaluation of CBR-2092, a novel rifamycin-quinolone hybrid antibiotic: microbiology profiling studies with staphylococci and streptococci. *Antimicrob Agents Chemother.* 2008 Jul;52(7):2324-34. doi: 10.1128/AAC.01651-07. PubMed PMID: 18443106; PubMed Central PMCID: PMC2443883.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481